- Home
- MUJ vs KROS Comparison
MUJ vs KROS Comparison
Compare MUJ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- KROS
- Stock Information
- Founded
- MUJ 1998
- KROS 2015
- Country
- MUJ United States
- KROS United States
- Employees
- MUJ N/A
- KROS N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- KROS Health Care
- Exchange
- MUJ Nasdaq
- KROS Nasdaq
- Market Cap
- MUJ 602.6M
- KROS 589.8M
- IPO Year
- MUJ N/A
- KROS 2020
- Fundamental
- Price
- MUJ $11.36
- KROS $11.41
- Analyst Decision
- MUJ
- KROS Buy
- Analyst Count
- MUJ 0
- KROS 11
- Target Price
- MUJ N/A
- KROS $45.33
- AVG Volume (30 Days)
- MUJ 108.0K
- KROS 2.0M
- Earning Date
- MUJ 01-01-0001
- KROS 02-26-2025
- Dividend Yield
- MUJ 4.36%
- KROS N/A
- EPS Growth
- MUJ N/A
- KROS N/A
- EPS
- MUJ N/A
- KROS N/A
- Revenue
- MUJ N/A
- KROS $651,000.00
- Revenue This Year
- MUJ N/A
- KROS $303.27
- Revenue Next Year
- MUJ N/A
- KROS N/A
- P/E Ratio
- MUJ N/A
- KROS N/A
- Revenue Growth
- MUJ N/A
- KROS 8037.50
- 52 Week Low
- MUJ $9.74
- KROS $9.78
- 52 Week High
- MUJ $11.70
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- MUJ 53.96
- KROS 22.44
- Support Level
- MUJ $11.21
- KROS $9.78
- Resistance Level
- MUJ $11.34
- KROS $11.63
- Average True Range (ATR)
- MUJ 0.10
- KROS 0.89
- MACD
- MUJ 0.05
- KROS 1.07
- Stochastic Oscillator
- MUJ 88.64
- KROS 23.61
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.